Speakers
Parallel Workshops
Implementing Medication for Opioid Use Disorder (MOUD) in carceral settings is challenging and rife with implementation challenges including misinformation, stigma, and resource and safety concerns. However, vast evidence suggests MOUD (e.g., buprenorphine, methadone, and naltrexone) offer evidence based benefits to individuals that lessen substance use while also lowering overdose risk and reducing recidivism. As carceral systems adopt MOUDs they must strategize to overcome these barriers. These strategies must be targeted and responsive so that acceptability and feasibility challenges do not stifle MOUDs critical and live-saving efforts. This presentation uses a case study from one U.S. state to highlight how one system navigated these challenges with some success, but failed in other areas. Implications of this study are crucial for any carceral systems hoping to implement MOUD to improve the lives of their staff and residents exponentially.